Open to debate. The motion: PDE5 inhibitors are a promising therapy for benign prostatic hyperplasia.
McVary
Kevin
K
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. k-mcvary@northwestern.edu
Tubaro
Andreas
A
De Nunzio
Cosimo
C
D003363:Cost Control; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D058986:Phosphodiesterase 5 Inhibitors